PMID- 33685189
OWN - NLM
STAT- MEDLINE
DCOM- 20211021
LR  - 20211021
IS  - 1802-5307 (Electronic)
IS  - 0862-495X (Linking)
VI  - 33
IP  - 6
DP  - 2020 Winter
TI  - Practical instructions for testing and targeted therapy in adult patients with 
      solid tumours with NTRK gene fusion in common clinical practice.
PG  - 414-419
AB  - BACKGROUND: Tropomyosin receptor kinase inhibitors (TRKi) have been shown to 
      produce a dramatic and long-lasting effect on tumours harbouring fusions of 
      neurotrophic receptor tyrosine kinase (NTRK) genes. Due to the low incidence of 
      these molecular aberrations in common types of solid adult tumours, the 
      identification of patients eligible for the treatment with TRK inhibitors in 
      routine clinical practice is a major challenge. The current methods for NTRK gene 
      fusion testing include immunohistochemistry (IHC), fluorescence in situ 
      hybridization (FISH), and several genomic assays using next-generation sequencing 
      (NGS). After considering the characteristics of these tests, we recommend 
      two-step testing for clinical practice in tumours with a low incidence of NTRK 
      gene fusions. In the first step, a fresh or archival formalin fixed paraffin 
      embedded (FFPE) sample is tested using a validated IHC method. If the IHC result 
      is positive, verification using RNA-based should follow, preferably using fresh 
      tissue sample. If fresh tissue bio-psy cannot be obtained, e.g. due to a 
      disproportionate risk or discomfort for the patient, an archival FFPE sample may 
      be used for testing. For tumours with high incidence of NTRK gene fusions, we 
      recommend upfront NGS sequencing. Larotrektinib is currently the only TRK 
      inhibitor registered in the EU. Although entrektinib, another TRK inhibitor, is 
      not yet registered in the EU, it is currently available in the Czech Republic 
      within an Early Access Programme. PURPOSE: The aim of this paper is to provide 
      concise and clear guidance on testing for the presence of NTRK gene fusions and 
      indications for the treatment with TRK inhibitors in the routine clinical 
      oncology practice.
FAU - Buchler, Tomas
AU  - Buchler T
FAU - Dundr, Pavel
AU  - Dundr P
FAU - Finek, Jindrich
AU  - Finek J
FAU - Kiss, Igor
AU  - Kiss I
FAU - Matej, Radoslav
AU  - Matej R
FAU - Melichar, Bohuslav
AU  - Melichar B
FAU - Michal, Michal
AU  - Michal M
FAU - Petruzelka, Lubos
AU  - Petruzelka L
LA  - eng
PT  - Journal Article
PT  - Review
TT  - Prakticky navod pro testovani a cilenou lečbu dospělych pacientů 
      se solidnimi nadory s genovou fuzi NTRK v běžne klinicke praxi.
PL  - Czech Republic
TA  - Klin Onkol
JT  - Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti
JID - 9425213
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.1 (Receptor Tyrosine Kinase-like Orphan Receptors)
SB  - IM
MH  - Adult
MH  - Antineoplastic Agents/*therapeutic use
MH  - Gene Fusion
MH  - Humans
MH  - Neoplasms/*drug therapy/*genetics
MH  - Practice Guidelines as Topic
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Receptor Tyrosine Kinase-like Orphan Receptors/*genetics
OTO - NOTNLM
OT  - neurotrophic receptor kinase - targeted molecular therapy - entrektinib - 
      larotrektinib - neoplasms
EDAT- 2020/01/01 00:00
MHDA- 2023/02/25 06:00
CRDT- 2021/03/09 05:38
PHST- 2021/03/09 05:38 [entrez]
PHST- 2020/01/01 00:00 [pubmed]
PHST- 2023/02/25 06:00 [medline]
AID - 125200 [pii]
PST - ppublish
SO  - Klin Onkol. 2020 Winter;33(6):414-419.